| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.7 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.017 | 0.8 |
| mRNA | Obatoclax Mesylate | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.8 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | 0.02 | 0.8 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.0096 | 0.8 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | -0.0088 | 0.8 |